Is Alpha Tau Medical Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: DRTS) stock is to Strong Buy DRTS stock.
Out of 2 analysts, 1 (50%) are recommending DRTS as a Strong Buy, 1 (50%) are recommending DRTS as a Buy, 0 (0%) are recommending DRTS as a Hold, 0 (0%) are recommending DRTS as a Sell, and 0 (0%) are recommending DRTS as a Strong Sell.
What is DRTS's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: DRTS) forecast ROE is N/A, which is considered weak.
What is DRTS's Price Target?
According to 2 Wall Street analysts that have issued a 1 year DRTS price target, the average DRTS price target is $16.00, with the highest DRTS stock price forecast at $23.00 and the lowest DRTS stock price forecast at $9.00.
On average, Wall Street analysts predict that Alpha Tau Medical's share price could reach $16.00 by Sep 20, 2024. The average Alpha Tau Medical stock price prediction forecasts a potential upside of 387.8% from the current DRTS share price of $3.28.
What is DRTS's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: DRTS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.07%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.